Skip to main content
. 2017 Dec 16;9(10):9480–9488. doi: 10.18632/oncotarget.23840

Figure 5. Relative risk of ALK-TKIs-associated all-grade and high-grade AST elevation versus control from randomized controlled trials.

Figure 5